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Proteasome–lysosomeWe introduce a stochastic model describing aggregation of misfolded proteins and degradation by
the protein quality control system in a single cell. Aggregate growth is contrasted by the cell quality
control system, that attacks them at different stages of the growth process, with an efﬁciency that
decreases with their size. Model parameters are estimated from experimental data. Two qualita-
tively different behaviors emerge: a homeostatic state, where the quality control system is stable
and aggregates of large sizes are not formed, and an oscillatory state, where the quality control sys-
tem periodically breaks down, allowing for formation of large aggregates. We discuss how these
periodic breakdowns may constitute a mechanism for the development of neurodegenerative
diseases.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Protein aggregation and formation of amyloid ﬁbrils are a sub-
ject of intense experimental and theoretical study. A main motiva-
tion is that such phenomena, and in particular the formation of
cytotoxic pre-amyloid species and larger inclusion bodies, is a
common theme underlying most known neurodegenerative dis-
eases [1–7]. Besides structural studies, several attempts have been
made to build up coarse-grained models, describing the kinetic of
the aggregation process in vitro. One of their key features is the
existence of a nucleation mechanism [8]. During later stages of
the aggregation, the possibility of aggregates to fragment also be-
comes important [9,10]. Recent works reported that, in some cases,
in vitro ﬁlament growth is not gradual but occurs in almost dis-
crete steps [11,12]. Several other models have been proposed,
including more detailed mechanisms [13,14].
While in vitro amyloid aggregation is quite well characterized,
much less is known about the corresponding dynamics in vivo.
This is the main focus in this paper. Beside the limitations of sin-
gle-cell and culture experiments compared to the in vitro case,
there are also a number of theoretical challenges. For example,
aggregates typically grow in vitro on timescales of hours or days.In contrast, it is unclear why aggregates grow in vivo in a time
frame of week to years, as shown by long-term imaging of amyloid
accmulation in murine brains [15].
A large number of studies demonstrates that the ubiquitin–pro-
teasome system (UPS) is implicated in neurodegenerative disor-
ders [16,17]. It has been suggested that insoluble inclusion
bodies form due to an impaired UPS function, given that proteaso-
mal inhibitors lead to inclusion bodies and neuronal apoptosis
[18–20]. Proteasomal activity is reduced in Parkinsons Disease
(PD), characterized by intracellular amyloid deposits of the protein
a-synuclein (aSN) [21]. Pathogenic aSN mutants (found in familial
versions of PD) can as oligomers and ﬁbrils bind to proteasome and
inhibit it directly [22], while overproduction of mutant aSN makes
cells sensitive to proteasome inhibitors [23]. Further, aggregated
proteins per se impair proteasomal functioning [24–26]. Another
degradation pathway involves macroautophagy, an intracellular
catabolic system in which cytoplasmic components are delivered
into lysosomes for degradation. Indeed, neurodegenerative dis-
eases appear to be most closely linked to macroautophagy. Parkin,
a protein that is mutated in autosomal recessive forms of PD, ap-
pears to act as a signal for selective autophagy of dysfunctional
mitochondria in PD [27], while the pathogenic aSN mutants
A53T and A30P also bind a receptor for chaperone-mediated
autophagy, inhibiting this pathway [28]. There is a relation to
UPS in that protein aggregates can be degraded by selective
autophagy via ubiquitin tagging [29,30], while impairment of
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ubiquitin-positive inclusions [31,32]. Furthermore, A53T aSN over-
production inhibits both proteasomal and lysosomal activity [33].
In a previous study, we explored in a simple two-stage model
the consequences of the interaction between a-SN and the UPS
system [34]. We found a transition between a state in which the
UPS system effectively prevents aggregation, and one in which spi-
ky oscillations are observed. During such spikes, the UPS is im-
paired, allowing for growth of aggregates. However, a more
mechanicistic description of the aggregation kinetics in vivo is still
lacking, making parameter estimation from experimental data
problematic. Furthermore, we did not include the possibility of
lysosomal degradation.
To address these issues, we propose a mechanicistic model
describing the battle between protein aggregation and the quality
control system (QCS) in a single cell. The aggregation process is
implemented stochastically. Aggregates are formed when a nucle-
ation threshold is passed, and grow according to the existing con-
centration of monomers, as in [13]. Further, large aggregates can
break into smaller fragments. We study the interaction of this
dynamics with the response of the protein QCS. Its action is mod-
eled as an enzymatic degradation, whose efﬁciency depends on the
size of the aggregate. In the ﬁrst part of the manuscript, we identify
this system with the UPS, as it is better characterized from a bio-
chemical point of view. As larger fragments are more likely to be
attacked by autophagy, in the second part we generalize of the
model to describe lysosomal degradation. Most of the parameters
in the our model have been measured experimentally. For some
of them, it is difﬁcult to ﬁnd quantitative estimates, due to current
limitations in the ability to monitor cellular aggregation with a
precision approaching that of in vitro studies. However, we antic-
ipate that the rapid development in imaging and e.g. ﬂuorescence
labeling techniques will close this gap in the foreseeable future
[15,35–37].
2. Model
We deﬁne fn as the number of free aggregates made up of n
monomers present in a cell, so that f1 is the number of free mono-
mers, or aggregation-prone proteins. We model the action of the
QCS as an enzymatic degradation: the agent produced by the cell
degrading the ﬁlaments, denoted by E, can bind to a ﬁlament of
size n (fn) to form a complex Cn, which is then degraded. While
the enzymatic reaction scheme is standard for protein degradation
such as that operated by the proteasome, it should be considered
more speculative for a large body such as a lysosome. However,
it captures the basic essence of a degradation operating after some
processing time also in this case. We therefore adopt the sameFig. 1. Scheme of the reactions: protein aggregation (top panel) and degradation by the q
bottom left panel. The ‘‘enzyme’’ represents either the proteasome or the lysosome, depscheme in the two cases, but modify the corresponding parameters
to take into account the different size and efﬁciency of the two
agents. The interplay between fn,E and Cn is summarized in the
reactions (R1)–(R7) of Fig. 1 and discussed below.
In analogy with existing literature [9,13], we describe the
dynamics of aggregate formation in terms of two basic processes:
(R1) growth by attachment of monomers to the ﬁbril ends, and
(R2) random breakage of aggregates into smaller fragments. Reac-
tions (R1) and (R2) occur at rates c and b, respectively. We also
introduce a simple nucleation mechanism: the rate at which two
monomers bind (R10) f1 þ f1!c
0
f2 is much smaller than (R1), i.e.
c0  c, corresponding to a barrier for dimer formation. The dynam-
ics encoded in (R1), (R10) and (R2) has shown to be consistent with
results of in vitro aggregation experiments [13]. In addition, we
consider a constant production of monomers at rate l (R3).
Molecules of the degradation enzyme E are produced at rate a
(R4) and degraded at rate d per molecule (R5). Degradation of
aggregates is assumed to take place as a two-step process. First,
E can bind to a ﬁbril of a given size n to form a complex Cn (R6).
We assume that monomers are not attacked by the QCS. Then, in
a time proportional to n, the aggregate is entirely degraded, while
the enzyme is released (R7). The choice of a degradation time being
proportional to n is a simpliﬁcation, due to the level of biochemical
characterization of the degrading agents. A more general assump-
tion would be to introduce functions g(n) and m(n), different for dif-
ferent agents, describing the spectrum of aggregates that each of
them can effectively bind and degrade. Finally, notice that E repre-
sents the number of units of the free degradation enzyme, not
counting those bound to aggregates.
3. Choice of model parameters
In this section, we discuss the estimates of the rates. All rates
are expressed per molecule per day (per cell). For binary reactions,
it is relevant to estimate the cell volume. The average diameter of a
dopaminergic neuron is from 10 to 20 lm (see e.g. [41]). This cor-
responds to an approximate cell volume of v  1011l.
Studies on insulin [39] report ﬁbril growth rates around 0.3
monomers per ﬁbril per second at a monomer concentration of
0.17 mM. Similar studies on other molecules [40] report similar
values. Given the cell volume above, one single monomer in a cell
corresponds to a concentration of 1/(NAv)  2  1013M where NA
is the Avogadro number. The growth rate per ﬁbril per monomer
is then 0.25  109 s1, i.e. approximately 2  105 monomers
per ﬁbril per day. Ref. [39] estimates from reaction rate arguments
that one every 105 encounter events between ﬁlaments and mono-
mer results in attachment. Estimates of nucleation barriers lead to
an activation rate being 8–9 orders of magnitudes smaller than theuality control system (bottom right panel). The dynamics of the QCS is shown in the
ending on the parameters choice.
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since cell condition can signiﬁcantly favor/disfavor the formation
of nucleation seeds. We choose a relatively high nucleation rate,
c0 = 2  1010 per day per molecule pair per cell volume. We ﬁx a
ﬁlament breakage rate b = 103 [13]. The production rate of mono-
mers a is left as a free parameter. Since its value is typically large,
to speed up the simulations we implemented an alternative reac-
tion in which 100 monomers at a time are produced with a rate
a/100. We checked in shorter simulations that such approximation
does not alter signiﬁcantly the results, thanks to the typical high
numbers of monomers.
We move now to the parameters related to the proteasome.
Proteasome lifetime is estimated to be 8–15 days in the cell
[42,43], leading to a degradation rate d = 0.1. The proteasome pro-
duction rate a is left as a free parameter. On general grounds, we
may expect the proteasome to bind better to the ﬁlaments than
to a monomer, leading to a complex formation g being larger than
c. We choose g = 0.02, corresponding to one successful binding
event every 100 encounters. A lower value of g would make the
proteasome less effective and simply result in a higher threshold
value for a to observe oscillations, without affecting the qualitative
features of the model. As the degradation rate of individual mole-
cules by the proteasome is on the order of minutes, we choose
m = 103. Parameters corresponding to the lysosome case are dis-
cussed in the results section.
4. Results
Our model of Fig. 1 describe reactions taking place in a single
cell. As numbers of molecules can be small, stochastic number ﬂuc-
tuations must be taken into account. Therefore, we implemented
the reactions via the Gillespie algorithm [38], where at each time
reactions are chosen proportionally to its probability. We start
our analysis by identifying the enzyme with the UPS, which we re-
fer to simply as the proteasome. Although there is little quantita-
tive information on the rates of breakdown of different
aggregates by proteasomes, this system has been studied in great
detail and is an undisputed central player in cellular degradation
pathways. Fig. 2, right shows the dynamics of the model with the
parameter choice from Section 3. After a short transient, the sys-
tem reaches an homeostatic state, where there is a chemical bal-
ance between proteasome concentration and the formation of
aggregates. In the ﬁgure, ﬁlaments and complexes (bound ﬁla-
ments) represent a sum over all sizes excluding the monomers f1,102
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Fig. 2. Homeostatic state. (left) Number of molecules (or aggregates) as a function of tim
not aggregated with this parameter choice, (right) Size distribution of free ﬁlaments. T
Parameters are: c = 2  105, c0 = 2  1010, b = 103, l = 6  104, a = 102, d = 0.1, g = 0.02
prediction of Eq. (5).that is
P
n>lfn and
P
n>1Cn. The ﬁgure shows that their concentra-
tions ﬂuctuate moderately around well deﬁned average values
which means that the proteasome is fully functioning and keeps
the total aggregate concentration down.
In this regime, aggregates of large size are unlikely to be formed.
Fig. 2 shows that the distribution of ﬁlament sizes is also station-
ary. In Appendix A, we study the stochiometric rate equations cor-
responding to our model, assuming that the fragmentation rate b
can be neglected compared to the degradation by the QCS. The
steady state solution shows that ﬁlament sizes are exponentially
distributed in this approximation. A comparison between this stea-
dy-state solution and the outcome of the Gillespie simulation of
the stochastic model is presented in the inset of Fig. 2, right panel.
The theoretical curve, without any free parameter, predicts very
closely the outcome of the simulation. The hypothesis that the
fragmentation rate is essentially irrelevant in this regime is there-
fore conﬁrmed. This is a radical difference compared with in vitro
results, where ﬁbrils grow at a much higher speed, up to a size
which is limited by the fragmentation rate and, in experiments,
by the available pool of aggregating peptide chains [13].
If the monomer production rate l is increased, homeostasis
breaks down and oscillations emerge (Fig. 3, left panel). Despite
the fact that simulations are stochastic, the period of the oscilla-
tions is remarkably regular. This is a consequence of the (average)
high copy number of all proteins involved. In this regime, there are
dramatic drops in proteasome concentration which stays low for
long periods of time, leading to a buildup of larger and larger ﬁbril-
lar aggregates. The QCS cannot cope in this case with the amount of
aggregates present in the system, resulting in a slower decay of the
aggregate size distribution. Eventually, bound proteasome is sud-
denly released after degradation of the aggregates, and a protea-
some concentration close to the homeostatic level is recovered.
This means that the system alternates between states in which
the QCS is functioning, and short periods in which the proteasome
is impaired. During such periods, aggregates of large size can be
produced, as shown in the right panel of Fig. 3. This is a conse-
quence of the fact that the growth dynamics, in the absence of deg-
radation, is faster than the recovery time of the QCS. In particular,
the largest formed aggregate is of a size about 103 monomers, as
opposed to 102 in the stable homeostatic case of Fig. 2. This max-
imum size clearly depends on the modeling choice of a linear
dependence of the degradation time on the aggregate size: assum-
ing a sharper dependence would make the QCS practically unable
to degrade large aggregates, providing a mechanism for LewyFilament size spectrum
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Fig. 3. Oscillatory state. Parameters are same as Fig. 2 but l is three times larger, l = 1.8  105. (left) number of molecules (or aggregates) as a function of time. (right) Size
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monomers constitute a small fraction of the total monomer pool.
This can be seen by comparing the almost overlapping dark and
light blue curves in Fig. 2. Conversely, in Fig. 3, one observe a large
fraction of monomers being aggregated during the periods when
the proteasome is impaired.
We conclude by remarking that, starting from the homeostatic
state of Fig. 2, oscillations can be triggered by varying also other
parameters; in particular, reducing the proteasome production rate
a, and/or the proteasome degradation efﬁciency m. On the other
hand, simulations (not shown) suggest that this triggering does
not depend much on the fragmentation rate, as ﬁlaments are
mostly actively degraded by the QCS.
4.1. Lysosomal degradation
Lysosomal degradation is less characterized biochemically com-
pared to proteasomal degradation. The lack of detailed experimen-
tal information about lysosomal turnover in the cell requires us to
explore a range of parameter values which we consider biologically
plausible. As previously discussed, we represent the lysosome as
an efﬁcient enzyme present in small numbers. We assumed a pro-
duction rate a = 1 lysosome per day, and a degradation rate of
d = 0.1 lysosomes per day which corresponds to an average of 10
lysosomes per cell at steady state. We assumed furthermore that
the rate at which the enzyme degrades aggregates (per aggregate
size) is m = 2  103, i.e. 20 times more efﬁcient than the
proteasome.102
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Fig. 4. Oscillations in the presence of lysosome. Parameters are as in Fig. 2, except a = 1 an
function of time, (right) size distribution of ﬁlaments. The period of oscillations is moreFig. 4 shows the results of a simulation for this parameter
choice. Even in this case we observe an oscillatory destabilization
of the homeostatic state, as the higher efﬁciency of lysosomes
are compensated by the lower numbers. The main difference with
Fig. 3 is that the period of the oscillations is much more irregular.
This is a consequence of the enzyme being present in small num-
bers, making stochastic ﬂuctuations more important. We veriﬁed
that we robustly obtained similar dynamical behaviors by varying
the parameters. The only observed differences when increasing the
efﬁciency (or the number) of lysosomes are that the crisis of the
QCS are less frequent and the typical recovery time faster. Con-
versely, decreasing further the lysosome efﬁciency drives the sys-
tem into a state in which the cell cannot cope most of the time
with the amount of growing ﬁlaments. Finally, we remark that,
while the same transition observed here is present in the deter-
ministic version of the model such as that of the rate equations
presented in the appendix, [1], noise is crucial as it enlarges the re-
gion of parameter space where oscillations should be expected. In-
deed, by simulating rate equations corresponding to the parameter
choices of Figs. 2 and 3, we found that they still are in the stable
homeostatic state.
5. Discussion
In this paper we studied the interplay between sequential
growth of amyloid ﬁbrils and its degradation by the QCS in a sin-
gle cell. The main result is that, in the regime in which the QCS
cannot cope with the amount of ﬁbrils, destabilisation of theFilament size spectrum
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d m = 2  103. As usual, (left) number of molecules (or aggregates, or lysosomes) as a
stochastic as the degrading agent is present in small numbers in this case.
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transition was already observed in the simple model presented
in [34], our new results demonstrate how oscillations can occur
for values of parameters being compatible, to the best of our
knowledge, with physiological conditions. The resulting oscilla-
tions are characterized by time lapses in which the QCS is func-
tioning and prevents aggregation, separated by time windows in
which the QCS is impaired and ﬁbrils of large sizes can grow.
The period of such oscillations depends on the parameter choice
but is typically on the scale of months. This behavior strongly
contrast with the dynamics in the absence of the QCS [13], which
is much faster and where oscillations do not appear. The model
thus predicts that the net growth of aggregates is a slow process,
reminiscent to the remarkably slow development of neurodegen-
erative diseases [15]. Finally, we have shown that when the agent
degrading the aggregates is present in large numbers, the result-
ing oscillations tend to be very regular and almost deterministic,
while when the numbers are smaller oscillations are more
irregular.
There are clearly a number of generalisations one can consider
to account for more accurate experimental evidences, such as the
possibility of different interconnected repair systems, that attack
aggregates at different stages of the growth process and with dif-
ferent efﬁciencies depending on the aggregate size. Our model
should be considered as a minimal mechanistic model displaying
such non-trivial phenomenology.Acknowledgements
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Appendix A. Steady state solution of the rate equations
In this Appendix, we present the stochiometric rate equations
corresponding to the reactions in Fig. 1 and calculate their stea-
dy-state solution. We simplify the calculation by neglecting the
fragmentation rate, b = 0. In this approximation, the rate equations
can be simply written as
d
dt
f1 ¼ l cf1
X
n>1
fn
 !
 c0f 21
d
dt
f2 ¼ c0f 21  cf1f2  gEf2
d
dt
fn ¼ cf1ðfn1  fnÞ  gEfn for n > 2
d
dt
Cn ¼ gfnE mnCn
d
dt
E ¼ a dE
X
n>1
gEfn  mnCn
 
ð1Þ
where we assumed that, for all proteins involved, the numbers per
cell are large enough to be considered as continuous variables. From
the last two equations, we readily obtain that at steady state E = a/d
and Cn = nafn/(dm). To obtain an expression for the ﬁbril distribution
fn, we deﬁne r ¼
P
n>1fn. Writing the equation for r (i.e. summing
the equations for fn for 2 6 n <1) and imposing steady state yields
c0f 21 
ga
d
r ¼ 0! r ¼ dc
0
ga
f 21 : ð2Þ
Substituting into the equation for f1 leads todcc0
ga
f 31 þ c0f 21  l ¼ 0: ð3Þ
One can show by standard methods that the above third order
equation admits a unique positive real solution. Let us call this po-
sitive solution f . Substituting f into the equations for f2 and for the
fn, n > 2 leads to an exponential distribution
fn ¼ A expðBnÞ for n > 1 ð4Þ
characterized by the parameters
A ¼ c
0 cf þ g ad
 
c2
B ¼ ln c
f þ gad
cf
 !
:
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